According to a recent survey, 75% of hospitals utilize their internal pharmacy staff to prepare and create drug reviews for P&T. Gathering the supporting data about these drugs requires searching multiple sources: clinical journals, FDA announcements, medical conference summaries, presentations, industry newsletters, and pharmaceutical company announcements. This process takes clinical pharmacists away from participating at the point of care, between 10 and 20 hours per month!
Yet, survey respondents either wait until after a drug received FDA approval to begin evaluating the drugs' appropriateness for their formulary; only review high cost drugs prior to FDA approval; or sometimes review a practice-changing drug prior to approval.
One could postulate that this practice of post FDA approval review aligns with point-of-care availability of newly approved drug information in knowledgebases feeding point-of-care patient record software.
However, pre-FDA efficient drug approval review is possible by re-purposing staff time toward analysis rather than data-gathering. The following benefits accrue:
Evidence based decision support within the Pharmaceutical Pipeline Tracker includes a summary of efficacy and safety along with the latest news and analysis from clinical journals, FDA announcements, medical conference summaries, presentations, industry newsletters, and pharmaceutical company announcements. As a bonus, there is additional evidence via links to published studies via PubMed.
It’s time to re-think how you prepare for P&T new drug reviews.
Click here for access to The Pharmaceutical Pipeline Tracker for only $339! Utilize all of the functions and access all of the evidence based intelligence about 888 investigational drugs in the pipelines of over 400 pharmaceutical companies. Access includes links to 1546 late stage clinical trial results. Limited time offer. No automatic renewal.
Stay informed, subscribe to the
Prescribe Right Pharmaceutical Pipeline Tracker
Latest Tweets from Prescribe Right